Allorion Therapeutics (Allorion) has entered into an exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC). Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,086 GBX | -1.77% |
|
-3.70% | +14.02% |
Jul. 02 | ASTRAZENECA : Jefferies reaffirms its Neutral rating | ZD |
Jul. 02 | Deutsche Bank cuts Quilter, ups Polar Capital | AN |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.02% | 241B | |
+55.55% | 823B | |
+42.31% | 641B | |
-6.83% | 352B | |
+17.15% | 324B | |
+7.09% | 301B | |
+1.64% | 223B | |
+13.66% | 218B | |
+7.87% | 167B | |
-3.33% | 160B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca